Revolution Medicines price target raised to $200 from $140 at Evercore ISI

Evercore ISI raised the firm’s price target on Revolution Medicines (RVMD) to $200 from $140 and keeps an Outperform rating on the shares. Daraxonrasib’s RASolute 302 readout is “a true game-changer” with a “stunning OS benefit” that accelerates timelines across the board, says the analyst, who now bakes in an earlier launch, bigger peak sales, and a higher probability of success in pancreatic ductal adenocarcinoma.